<DOC>
	<DOCNO>NCT02935712</DOCNO>
	<brief_summary>This study phase I , first time human ( FiH ) , randomize , single-blind , placebo-controlled , SAD study male patient T2DM , perform single study center . The study consist 2 part , ( A B ) 60 male patient T2DM age 18 65 year include .</brief_summary>
	<brief_title>Assessment Safety , Tolerability Pharmacodynamics After Administration One Dose AZD8601 Male Patients With Type II Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>Part A ass safety tolerability SAD intradermal ( ID ) injection AZD8601 ( modify VEGF-A RNA ) Part B evaluate pharmacodynamic effect ID injection AZD8601 forearm skin . AZD8601 VEGF-A modify RNA development novel modality local production human VEGF-A protein develop treatment diabetic patient ulcer . Each patient Part A involve study 7 8 week . Each patient Part B involve study 5 6 week . Safety tolerability variable include Adverse event ( AEs ) , Vital sign ( BP , pulse ) , ECG , Hematology , Clinical chemistry , Urinalysis . The study include patient T2DM stable dos 1 2 anti-diabetic medication . The T2DM patient may also medications comorbidities hypertension , dyslipidemia , hyperuricemia , thyroid disorder , benign prostate hyperplasia etc . ( e.g . diuretic , statin , allopurinol , thyroxin ) , must healthy otherwise .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Male patient mild T2DM age 18 65 year suitable vein cannulation repeat venipuncture . 3 . Have body mass index ( BMI ) 20 35 kg/m2 inclusive weigh least 50 kg . 4 . Able understand , read speak German language . 5 . T2DM diagnosis least 1 year time screen visit . 6 . T2DM treat diet exercise alone 2 oral antidiabetic drug . 7 . Have stable glycemic control indicate change treatment within 3 month prior enrolment . 8 . Hemoglobin A1c le 10.5 % screening ( HbA1c value accord international Diabetes Control Complications Trial standard ) . 9 . Fasting plasma glucose â‰¤ 11.0 mmol/L screening . 10 . Provision sign , write date informed consent optional genetic/biomarker research . 1 . History clinically significant disease disorder , opinion PI , may either put patient risk participation study , influence result patient 's ability participate study . 2 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week Day 1 3 . Any clinically significant abnormality clinical chemistry , hematology urinalysis result screen checkin , judge PI . The following strict criterion apply time screen Day 1 : Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal laboratory range Hemoglobin &lt; 11 g/dL and/or neutrophil &lt; 1500/mm3 and/or platelet &lt; 100 000/mm3 Creatinine &gt; 1.2 x upper limit normal ( ULN ) 4 . Uncontrolled inadequately control hypertension time screen and/or Day 1 rest systolic diastolic BP &gt; 150 mmHg &gt; 95 mmHg , respectively . Patients heart rate &lt; 50 bpm screen Day 1 exclude . 5 . Any clinically significant abnormality 12lead ECG screen judge PI . 6 . Any patient QT interval correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 m screening exclude . 7 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , antihepatitis B core ( HBc ) antibody , hepatitis C antibody human immunodeficiency virus ( HIV ) antibody . 8 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month Day 1 study . The period exclusion begin 3 month final dose previous study 1 month last visit , whichever longer . 9 . Plasma donation within 1 month screen blood donation/loss 400 mL 3 month prior screen . 10 . Current smoker smoke used nicotine product within previous 1 year cotinine cutoff local laboratory ) . 11 . Positive screen drug abuse , cotinine alcohol screen admission study center . 12 . Known suspected history alcohol drug abuse excessive intake alcohol judge PI . 13 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/ acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior admission long medication long halflife . Patients T2DM 1 2 antidiabetic medication need medication stable dos least 3 month . Patients T2DM also medications comorbidities hypertension , dyslipidemia , hyperuricemia , thyroid disorder , benign prostate hyperplasia etc . ( e.g . diuretic , statin , allopurinol , thyroxin ) need stable dose least 3 month . 14 . Involvement AstraZeneca study site employee close relative . 15 . Judgment PI patient participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 16 . Vulnerable patient , e.g. , keep detention , protect adult guardianship , trusteeship committed institution governmental juridical order . 17 . Reports significant history allergy soap , lotion , emollient , ointment , cream , cosmetic , adhesive latex . 18 . Reports history significant skin condition disorder , example , psoriasis , atopic dermatitis , etc . 19 . Reports history significant dermatologic cancer , example , melanoma squamous cell carcinoma . Basal cell carcinomas superficial successfully remove treat , involve investigative site acceptable . 20 . Presence forearm tattoo ( ) . 21 . History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen . 22 . History myocardial infarction , stroke , heart failure require hospitalization within 6 month prior time screening , history presence clinically significant diabetic retinopathy , history presence macular edema likely require LASER treatment within study period . 23 . Uncontrolled cardiovascular , hepatic , neurological endocrine disease . 24 . Use insulin , glitazones , warfarin amiodarone within 3 month enrolment use potent CYP450 inhibitor , e.g. , ketoconazole macrolide antibiotic within 14 day screen . 25 . Use anabolic steroid systemic treatment glucocorticoid within 3 month screen . 26 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge PI 27 . Patients communicate reliably PI . In addition , follow regarded criterion exclusion genetic research : 28 . Previous bone marrow transplant 29 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>AZD8601</keyword>
	<keyword>Type II Diabetes</keyword>
</DOC>